Report error Found 454 with Last Name = 'rao' and Initial = 'g'
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: <0.100nMAssay Description:Binding affinity to HIV-1 protease was determinedMore data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 0.100nMAssay Description:Inhibitory activity of the compound against HIV-I protease was determinedMore data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 0.5nMAssay Description:Compound was assayed for inhibition against HIV protease activityMore data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 0.600nMAssay Description:Compound was assayed for inhibition against HIV protease activityMore data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17 [215-477,S266A,N452Q](Human)
Vertex Pharmaceuticals
Vertex Pharmaceuticals
Affinity DataKi: 2nM ΔG°: -49.2kJ/molepH: 7.5 T: 22°CAssay Description:The compounds were tested for TACE inhibition using fluorescence resonance energy transfer (FRET) assay. TACE catalyzed cleavage of the substrate pep...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17 [215-477,S266A,N452Q](Human)
Vertex Pharmaceuticals
Vertex Pharmaceuticals
Affinity DataKi: 4.5nM ΔG°: -47.2kJ/molepH: 7.5 T: 22°CAssay Description:The compounds were tested for TACE inhibition using fluorescence resonance energy transfer (FRET) assay. TACE catalyzed cleavage of the substrate pep...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 7nMAssay Description:Binding affinity to HIV-1 protease was determinedMore data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17 [215-477,S266A,N452Q](Human)
Vertex Pharmaceuticals
Vertex Pharmaceuticals
Affinity DataKi: 8nM ΔG°: -45.7kJ/molepH: 7.5 T: 22°CAssay Description:The compounds were tested for TACE inhibition using fluorescence resonance energy transfer (FRET) assay. TACE catalyzed cleavage of the substrate pep...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17 [215-477,S266A,N452Q](Human)
Vertex Pharmaceuticals
Vertex Pharmaceuticals
Affinity DataKi: 10nM ΔG°: -45.2kJ/molepH: 7.5 T: 22°CAssay Description:The compounds were tested for TACE inhibition using fluorescence resonance energy transfer (FRET) assay. TACE catalyzed cleavage of the substrate pep...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17 [215-477,S266A,N452Q](Human)
Vertex Pharmaceuticals
Vertex Pharmaceuticals
Affinity DataKi: 10nM ΔG°: -45.2kJ/molepH: 7.5 T: 22°CAssay Description:The compounds were tested for TACE inhibition using fluorescence resonance energy transfer (FRET) assay. TACE catalyzed cleavage of the substrate pep...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 15nMAssay Description:Binding affinity to HIV-1 protease was determinedMore data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 15nMAssay Description:Compound was assayed for inhibition against HIV protease activityMore data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 17nMAssay Description:Binding affinity to HIV-1 protease was determinedMore data for this Ligand-Target Pair
Affinity DataKi: 17nM ΔG°: -43.9kJ/molepH: 7.4 T: 22°CAssay Description:A continuous assay was used in which the substrate is a synthetic peptide containing a fluorescent group (7-methoxycoumarin), which is quenched by en...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17 [215-477,S266A,N452Q](Human)
Vertex Pharmaceuticals
Vertex Pharmaceuticals
Affinity DataKi: 17nM ΔG°: -43.9kJ/molepH: 7.5 T: 22°CAssay Description:The compounds were tested for TACE inhibition using fluorescence resonance energy transfer (FRET) assay. TACE catalyzed cleavage of the substrate pep...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 17nMAssay Description:Compound was assayed for inhibition against HIV protease activityMore data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 17nMAssay Description:Compound was assayed for inhibition against HIV protease activityMore data for this Ligand-Target Pair
TargetGenome polyprotein/Non-structural protein 4A(Hepacivirus C)
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 20nMAssay Description:Inhibitory activity against hepatitis C virus NS3.4A proteaseMore data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 20nMAssay Description:Binding affinity to HIV-1 protease was determinedMore data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 20nMAssay Description:Binding affinity to HIV-1 protease was determinedMore data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 22nMAssay Description:Binding affinity of the compound against HIV-1 protease was determinedMore data for this Ligand-Target Pair
Affinity DataKi: 27nM ΔG°: -42.8kJ/molepH: 7.4 T: 22°CAssay Description:A continuous assay was used in which the substrate is a synthetic peptide containing a fluorescent group (7-methoxycoumarin), which is quenched by en...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 27nMAssay Description:Binding affinity to HIV-1 protease was determinedMore data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17 [215-477,S266A,N452Q](Human)
Vertex Pharmaceuticals
Vertex Pharmaceuticals
Affinity DataKi: 28nM ΔG°: -42.7kJ/molepH: 7.5 T: 22°CAssay Description:The compounds were tested for TACE inhibition using fluorescence resonance energy transfer (FRET) assay. TACE catalyzed cleavage of the substrate pep...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 29nMAssay Description:Binding affinity to HIV-1 protease was determinedMore data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17 [215-477,S266A,N452Q](Human)
Vertex Pharmaceuticals
Vertex Pharmaceuticals
Affinity DataKi: 30nM ΔG°: -42.5kJ/molepH: 7.5 T: 22°CAssay Description:The compounds were tested for TACE inhibition using fluorescence resonance energy transfer (FRET) assay. TACE catalyzed cleavage of the substrate pep...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 38nMAssay Description:Binding affinity to HIV-1 protease was determinedMore data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 38nMAssay Description:Binding affinity to HIV-1 protease was determinedMore data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 40nMAssay Description:Binding affinity to HIV-1 protease was determinedMore data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 42nMAssay Description:Inhibitory activity of the compound against HIV-I protease was determinedMore data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 43nMAssay Description:Binding affinity of the compound against HIV-1 protease was determinedMore data for this Ligand-Target Pair
Affinity DataKi: 43nM ΔG°: -41.6kJ/molepH: 7.4 T: 22°CAssay Description:A continuous assay was used in which the substrate is a synthetic peptide containing a fluorescent group (7-methoxycoumarin), which is quenched by en...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 50nMAssay Description:Binding affinity to HIV-1 protease was determinedMore data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17 [215-477,S266A,N452Q](Human)
Vertex Pharmaceuticals
Vertex Pharmaceuticals
Affinity DataKi: 50nM ΔG°: -41.3kJ/molepH: 7.5 T: 22°CAssay Description:The compounds were tested for TACE inhibition using fluorescence resonance energy transfer (FRET) assay. TACE catalyzed cleavage of the substrate pep...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 65nMAssay Description:Binding affinity to HIV-1 protease was determinedMore data for this Ligand-Target Pair